Anzeige
Mehr »
Login
Mittwoch, 26.03.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Gold-Highflyer startet durch - Mega-Bohrprogramm sorgt für Kursfantasie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Tradegate
25.03.25
21:48 Uhr
8,000 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,7508,05025.03.
7,8508,15025.03.

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMacquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/AKESO5
FrAkeso, Inc.: Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting56HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at...
► Artikel lesen
19.03.AKESO (09926): DATE OF BOARD MEETING1
17.03.Akeso's Penpulimab Gets NMPA Approval For First-Line Treatment Of Nasopharyngeal Cancer-
07.03.Akeso, Inc.: Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet69HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase...
► Artikel lesen
06.03.Akeso, Inc.: Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma59HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its...
► Artikel lesen
27.02.Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy98HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the...
► Artikel lesen
25.02.Akeso's Partner Summit, Pfizer Collaborate To Evaluate Ivonescimab In Solid Tumor Settings455NEW YORK CITY (dpa-AFX) - Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial collaboration with Pfizer Inc. (PFE)....
► Artikel lesen
AKESO Aktie jetzt für 0€ handeln
25.02.Akeso, Inc.: Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs155HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics...
► Artikel lesen
21.02.Akeso, Inc.: Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer77HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient...
► Artikel lesen
13.02.Akeso, Inc.: Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC70HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in...
► Artikel lesen
06.02.Akeso, Inc.: Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC77HONG KONG, Feb. 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the...
► Artikel lesen
23.01.Akeso, Inc.: Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine252HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature...
► Artikel lesen
22.01.Akeso, Inc.: Akeso Received Payment for the Development Collaboration on Tagitanlimab83HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research...
► Artikel lesen
04.12.24AstraZeneca's Enhertu and Akeso's bispecifics win national coverage in China as CAR-T therapies miss out again9
28.11.24AKESO (09926): VOLUNTARY ANNOUNCEMENT - THE INCLUSION IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST OF CADONILIMAB AND IVONESCIMAB3
01.11.24Akeso, Inc.: Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab104HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309...
► Artikel lesen
31.10.24Akeso, Inc.: Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared ...100HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled,...
► Artikel lesen
21.10.24AKESO (09926): NEXT DAY DISCLOSURE RETURN2
21.10.24AKESO (09926): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE-
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2